News
-
According to Kentucky-based AntiOp, the company has received Fast Track designation from the FDA for its intranasal naloxone for the reversal of opioid overdose. The company is co-developing the unit-dose nasal spray, its only product,… Read more . . .
-
ProStrakan, a subsidiary of Kyowa Hakko Kirin, has announced that it will acquire PecFent fentanyl nasal spray manufacturer Archimedes Pharma for £230 million in cash. Archimedes, which is based in Reading, UK, received European marketing… Read more . . .
-
Teva has announced that the FDA has accepted its new drug application for an albuterol dry powder inhaler for the treatment of asthma in patients aged 12 and older. In October 2013, Teva indicated that… Read more . . .
-
Following the submission by Teva of an ANDA for a generic mometasone furoate nasal spray, Merck has filed suit in the US District Court alleging infringement of US patent 6,127,353. The patent is due to… Read more . . .
-
Biotie Therapeutics has decided not to exercise its option to purchase Neurelis and is returning the rights to Neurelis’s lead product, NRL-1 intranasal diazepam for the treatment of epileptic seizures. Biotie paid $1 million for… Read more . . .
-
RDD Asia 2014 co-sponsor Aptar Pharma has announced that registration for the meeting is now open. According to the announcement, the organizers expect more than 200 OINDP specialists to attend the first Asian RDD meeting,… Read more . . .
-
The US Patent and Trade Office (USPTO) has awarded Aegis Therapeutics US Patent No. 8,772,231 for “dramatically stabilized insulin formulations suitable for metered nasal spray delivery or injection based upon Aegis’ patented Intravail transmucosal absorption… Read more . . .
-
According to Lightlake Therapeutics, the company has signed a contract with a manufacturer for commercial production of its intranasal naloxone for the reversal of opioid overdose. In December 2013, the company announced positive initial results… Read more . . .
-
Sunovion Pharmaceuticals has announced publication of data from a year-long safety study showing an approximately 40% lower risk of COPD exacerbation-related hospitalization or death due to respiratory disease for patients using Brovana arformoterol tartrate inhalation… Read more . . .
-
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Anoro Ellipta umeclidinium/vilanterol DPI for the treatment of COPD, GlaxoSmithKline and Theravance have announced. In April 2013, the companies announced that they had… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany